Marinus Pharmaceuticals Inc at American Epilepsy Society Annual Meeting Transcript
Okay, we're going to get started this morning. Alright. So good morning, everyone. Thank you for joining today. We're very excited to have our first in-person and virtual AES Investor Breakfast. I would like to take a moment just to go over our safe harbor statement before proceeding to today's agenda.
Okay, on to the agenda, we have quite a few folks here, a lot of new faces. So if we just start at the top, we have our Senior Vice President, Scientific Affairs, Alex Aimetti, who will provide a 2-year analysis of safety and effectiveness of Ganaxolone in patients with CDKL5 deficiency disorder. We'll turn to Dr. Ian Miller, Vice President of Clinical Affairs, who will discuss data that we presented at AES on our results of our TSC drug-drug interaction study with cannabinoids. Dr. Joe Hulihan, our Chief Medical Officer (inaudible) pro drug efforts and next steps.
Then, we'll turn over to our commercial group, where our Chief Commercial Officer, Christy Shafer, will discuss our early launch and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |